Status: Recruiting
A Post-Marketing Clinical Trial of Pemafibrate in Patients ｗith Hypercholesterolemia and Inadequate Response to Statins
To investigate the efficacy and safety of Pemafibrate 0.2 mg/day or 0.4 mg/day for 12 weeks in patients with hypercholesterolemia and inadequate response to statins, using placebo as a control.
Participants needed: 120
Trial details
Phase: Phase 4Age: 18+Biological sex: AllType: InterventionalSponsor: Kowa Company, Ltd.Updated: Jul 13, 2026Locations: 10
Eligibility criteria
Patients with hypercholesterolemia aged 18 years or older at the time of obtaini... [+10]
Patients who require administration of prohibited drugs during the post-marketin... [+27]